Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01769625 · ClinicalTrials.gov registry record · Phase 1
Changes in Biomarkers Using Prostaglandin Inhibitors
A Phase 1 study of Biomarker Change Linked to Breast Cancer, sponsored by Hartford Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT01769625 is a Phase 1 study of Biomarker Change Linked to Breast Cancer that has completed, run by Hartford Hospital. The registered enrollment target is 31 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01769625, a Phase 1 study of Biomarker Change Linked to Breast Cancer, has completed, sponsored by Hartford Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a biomarker study with the goal of measuring changes in proteins and gene methylation. This study is not intended for use in diagnosing, mitigating, treating, curing, or preventing disease. The purpose of this study is to determine if Vitamin D (cholecalciferol) alone and in combination with celecoxib (Celebrex, a non-steroidal anti-inflammatory drug, or NSAID), act together to decrease breast cancer risk by their effect on certain biological indicators (biomarkers) of breast cancer risk (called PGE2, COX-2, and 15-PGDH) and cell changes in the breast.
Conditions Studied
Interventions
- DRUG placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU
Study Locations (1)
North Dakota
- University of North Dakota - Grand Forks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2009-01 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01769625
The ClinicalTrials.gov registry entry for NCT01769625 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hartford Hospital, which has 75 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Biomarker Change Linked to Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU is the first listed.
NCT01769625 reports 1 study location spanning 1 distinct geographic area - top geographies include North Dakota.
Frequently Asked Questions
What is clinical trial NCT01769625 about?
NCT01769625 is a clinical study titled "Changes in Biomarkers Using Prostaglandin Inhibitors". This is a biomarker study with the goal of measuring changes in proteins and gene methylation. This study is not intended for use in diagnosing, mitigating, treating, curing, or preventing disease. The purpose of this study is to determine if Vitamin D (cholecalciferol) alone and in combination wit...
What is the current status of trial NCT01769625?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2009-01. Estimated completion is 2016-11.
What conditions does trial NCT01769625 study?
This clinical trial studies the following conditions: Biomarker Change Linked to Breast Cancer.
What interventions are being tested in trial NCT01769625?
The interventions under investigation include: placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU (DRUG).
Who is sponsoring clinical trial NCT01769625?
This trial is sponsored by Hartford Hospital, which has 75 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01769625 being conducted?
This trial has 1 study location across North Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.